Voyager Therapeutics (NASDAQ:VYGR) Stock Price Crosses Below Fifty Day Moving Average – What’s Next?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares crossed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $3.21 and traded as low as $2.64. Voyager Therapeutics shares last traded at $2.68, with a volume of 719,918 shares.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on VYGR shares. HC Wainwright restated a “buy” rating on shares of Voyager Therapeutics in a research report on Thursday, August 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Voyager Therapeutics in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Voyager Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $16.50.

Voyager Therapeutics Stock Down 4.3%

The stock has a market capitalization of $165.14 million, a price-to-earnings ratio of -1.49 and a beta of 1.32. The company has a 50 day simple moving average of $3.21 and a 200-day simple moving average of $3.60.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.08. The company had revenue of $3.17 million during the quarter, compared to the consensus estimate of $4.52 million. Voyager Therapeutics had a negative net margin of 312.63% and a negative return on equity of 57.92%. As a group, sell-side analysts anticipate that Voyager Therapeutics, Inc. will post -1.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Voyager Therapeutics

Large investors have recently bought and sold shares of the stock. ProShare Advisors LLC acquired a new position in shares of Voyager Therapeutics during the fourth quarter valued at about $44,000. Spark Investment Management LLC acquired a new stake in shares of Voyager Therapeutics in the 2nd quarter valued at about $47,000. Ieq Capital LLC acquired a new stake in shares of Voyager Therapeutics in the 2nd quarter valued at about $48,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Voyager Therapeutics in the 2nd quarter valued at about $61,000. Finally, Caitong International Asset Management Co. Ltd increased its position in Voyager Therapeutics by 42,410.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 15,729 shares of the company’s stock valued at $62,000 after buying an additional 15,692 shares in the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc (NASDAQ: VYGR) is a clinical-stage biotechnology company focused on developing gene therapies and other medicines for diseases of the central nervous system. The company seeks to address neurological conditions by delivering therapeutic genetic material to specific cells in the brain and spinal cord.

Voyager’s technology platform includes its TRACER AAV capsid discovery platform, which is designed to identify adeno-associated virus capsids that can cross the blood-brain barrier and enable broader distribution of gene therapies.